GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Intangible Assets

INTS (Intensity Therapeutics) Intangible Assets : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Intensity Therapeutics's intangible assets for the quarter that ended in Sep. 2024 was $0.00 Mil.


Intensity Therapeutics Intangible Assets Historical Data

The historical data trend for Intensity Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Intangible Assets Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
- - - - -

Intensity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Intensity Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Intensity Therapeutics  (NAS:INTS) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Intensity Therapeutics Intangible Assets Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Intensity Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
Executives
Emer Leahy director 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers officer: Executive VP of CF 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender director, 10 percent owner, officer: President and CEO 765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg director PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski officer: Interim CFO 61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880

Intensity Therapeutics Headlines

From GuruFocus